Background

Existing research suggests patients with blood group O are less likely to develop pancreatic ductal adenocarcinoma (PDAC) compared to those with non-O blood groups, and that survival from PDAC may be affected by ABO blood type. This study assessed survival outcomes in PDAC patients who underwent pancreatoduodenectomy (PD) in one health system.

Methods

From 2010 to 2017, demographic, operative, chemotherapy and survival data for patients undergoing PD at Emory Healthcare were reviewed. Patients with blood type AB were excluded due to small sample size. The relationship between ABO blood group and survival was analyzed using Kaplan–Meier survival curves and multivariate cox proportional regression analysis.

Results

Of 449 PDAC patients assessed, 204 (45.4%), 60 (13.4%) and 185 (41.2%) were blood groups A, B and O, respectively. Patients were well matched in clinicopathologic characteristics. Median survival did not differ by blood group (p = 0.82), and this relationship remained insignificant on cox regression analysis (p = 0.15). On multivariate analysis, lymph node positivity (p < 0.001) and increasing age (p = 0.001) were associated with reduced survival.

Conclusion

In contrast to recent reports, this larger study found that blood group did not impact overall survival among patients undergoing PD for PDAC.

中文翻译：

---

ABO血型与胰腺导管腺癌胰十二指肠切除术后生存率的关系

背景

现有研究表明，与非 O 血型患者相比，O 型血患者患胰腺导管腺癌 (PDAC) 的可能性较小，而且 PDAC 的存活率可能受 ABO 血型的影响。本研究评估了在一个卫生系统中接受胰十二指肠切除术 (PD) 的 PDAC 患者的生存结果。

方法

从 2010 年到 2017 年，审查了 Emory Healthcare 接受 PD 患者的人口统计学、手术、化疗和生存数据。由于样本量小，AB血型患者被排除在外。使用 Kaplan-Meier 生存曲线和多变量 cox 比例回归分析分析 ABO 血型与生存之间的关系。

结果

在评估的 449 名 PDAC 患者中，204 名 (45.4%)、60 名 (13.4%) 和 185 名 (41.2%) 分别为血型 A、B 和 O。患者的临床病理特征匹配良好。中位生存期没有因血型而异（p = 0.82），并且这种关系在 cox 回归分析中仍然不显着（p = 0.15）。在多变量分析中，淋巴结阳性 (p < 0.001) 和年龄增加 (p = 0.001) 与生存率降低有关。

结论

与最近的报告相反，这项更大的研究发现，血型不会影响接受 PDAC PD 患者的总生存期。